Mylan Stock Rating Reaffirmed by Keefe, Bruyette & Woods (MYL)
Mylan (NYSE:MYL)‘s stock had its “outperform” rating reaffirmed by stock analysts at Keefe, Bruyette & Woods in a report issued on Friday. They currently have a $55.00 target price on the stock, down from their previous target price of $60.00. Keefe, Bruyette & Woods’ target price would indicate a potential upside of 19.96% from the company’s current price.
Shares of Mylan (NYSE:MYL) opened at 45.85 on Friday. Mylan has a one year low of $34.46 and a one year high of $57.52. The stock has a 50-day moving average of $50.66 and a 200-day moving average of $49.55. The company has a market cap of $17.136 billion and a price-to-earnings ratio of 29.04.
Mylan (NYSE:MYL) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.69 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.73 by $0.04. The company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.88 billion. During the same quarter last year, the company posted $0.68 earnings per share. Mylan’s revenue was up 7.9% compared to the same quarter last year. Analysts expect that Mylan will post $3.36 EPS for the current fiscal year.
MYL has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Mylan in a research note on Friday. They now have a $49.00 price target on the stock. Separately, analysts at RBC Capital downgraded shares of Mylan from an “outperform” rating to a “sector perform” rating in a research note on Friday. They now have a $53.00 price target on the stock, down previously from $60.00. Finally, analysts at Citigroup Inc. downgraded shares of Mylan from a “buy” rating to a “neutral” rating in a research note on Friday, July 25th. They now have a $57.00 price target on the stock, down previously from $61.00. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $54.45.
Mylan Inc (NYSE:MYL) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.
Receive News & Ratings for Mylan Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.